ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2015
Health state utilities associated with attributes of treatments for hepatitis C.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Health utility values associated with pharmaceutical treatment process attributes: a systematic review and meta-analysis.Health and quality of life outcomes · 2026Pooled it
- Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence.PharmacoEconomics · 2017Pooled it
- Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.International journal of clinical pharmacy · 2020Trial
- Estimating the impact of pill burden on health utilities in hemodialysis therapy.Scientific reports · 2025Article
- Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective.Clinical drug investigation · 2025Article
- Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States.International journal of clinical pharmacy · 2024Article
- The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.Frontiers in public health · 2024Article
- Implementing a Health Utility Assessment Platform to Acquire Health Utilities in a Hemodialysis Outpatient Setting: Feasibility Study.JMIR formative research · 2022Article
- The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing-Remitting Multiple Sclerosis.PharmacoEconomics · 2022Article
- First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.The oncologist · 2021Article
- Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma.Cancer medicine · 2021Article
- Economic evaluation of process utility: elucidating preferences for a non-invasive procedure to treat restenosis.Health economics review · 2021Article
- Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Article
- Assessing potential cures: are there distinctive elements of value beyond health gain?Journal of comparative effectiveness research · 2021Article
- Health state utilities associated with treatment for transfusion-dependent β-thalassemia.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2019Article
- Health state utilities associated with post-surgical Staphylococcus aureus infections.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension.Patient preference and adherence · 2018Article
- Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.Patient preference and adherence · 2018Article
- Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCost-utility analyses are frequently conducted to compare treatments for hepatitis C, which are often associated with complex regimens and serious adverse events. Thus, the purpose of this study was to estimate the utility associated with treatment administration and adverse events of hepatitis C treatments.
designHealth states were drafted based on literature review and clinician interviews. General population participants in the UK valued the health states in time trade-off (TTO) interviews with 10- and 1-year time horizons. The 14 health states described hepatitis C with variations in treatment regimen and adverse events.
resultsA total of 182 participants completed interviews (50% female; mean age = 39.3 years). Utilities for health states describing treatment regimens without injections ranged from 0.80 (1 tablet) to 0.79 (7 tablets). Utilities for health states describing oral plus injectable regimens were 0.77 (7 tablets), 0.75 (12 tablets), and 0.71 (18 tablets). Addition of a weekly injection had a disutility of -0.02. A requirement to take medication with fatty food had a disutility of -0.04. Adverse events were associated with substantial disutilities: mild anemia, -0.12; severe anemia, -0.32; flu-like symptoms, -0.21; mild rash, -0.13; severe rash, -0.48; depression, -0.47. One-year TTO scores were similar to these 10-year values.
conclusionsAdverse events and greater treatment regimen complexity were associated with lower utility scores, suggesting a perceived decrease in quality of life beyond the impact of hepatitis C. The resulting utilities may be used in models estimating and comparing the value of treatments for hepatitis C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.